Emalex Biosciences

Emalex Biosciences

Biotechnology, 330 N Wabash Ste 3500, Chicago, Illinois, 60611, United States, 11-50 Employees

emalexbiosciences.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 13*********

Who is EMALEX BIOSCIENCES

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidat...

Read More

map
  • 330 N Wabash Ste 3500, Chicago, Illinois, 60611, United States Headquarters: 330 N Wabash Ste 3500, Chicago, Illinois, 60611, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from EMALEX BIOSCIENCES

Emalex Biosciences Org Chart and Mapping

Employees

Sarah Horine

Senior Director, Statistics, Statistical Programming and Data Management

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Emalex Biosciences

Answer: Emalex Biosciences's headquarters are located at 330 N Wabash Ste 3500, Chicago, Illinois, 60611, United States

Answer: Emalex Biosciences's phone number is 13*********

Answer: Emalex Biosciences's official website is https://emalexbiosciences.com

Answer: Emalex Biosciences's revenue is $1 Million to $5 Million

Answer: Emalex Biosciences's SIC: 2834

Answer: Emalex Biosciences's NAICS: 325412

Answer: Emalex Biosciences has 11-50 employees

Answer: Emalex Biosciences is in Biotechnology

Answer: Emalex Biosciences contact info: Phone number: 13********* Website: https://emalexbiosciences.com

Answer: Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access